SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe the dose limiting toxicities (DLT) of SKLB1028 when
combined with cytarabine/ daunorubicin remission induction in a 7+3 schedule. Safety and
tolerability of SKLB1028 will also be evaluated. This study will also characterize the
pharmacokinetics (PK) of SKLB1028 when given in combination with cytarabine/daunorubicin
remission induction and high-dose cytarabine (HiDAC) consolidation therapy in newly diagnosed
acute myeloid leukemia .